CLXPF News and Press, Canadian Lynx Pete Ltd From 07/20/21

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, is making ...

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused ...

The world is deeply interconnected, and we as people may sometimes feel overwhelmed by the happenings in the outside world. If an individual is overwhelmed, their body allows them to disconnect by removing their attention from the present as a form of healthy escape. Called disconnection...

Research has found that psychedelics possess therapeutic benefits that can be used to manage various mental health conditions, including anxiety and depression. Until recently, most studies conducted on these substances had been small scale. The Global Ayahuasca Project, which focused on ...

Cybin develops psychedelic therapeutics to treat psychiatric and neurological conditions. A veteran of the healthcare sector, CEO Doug Drysdale discusses why psychedelics are a better answer for mental health conditions like depression and addiction. Optimizing psychedelic deliver...

A study recently asked users of psychedelic substances to share their experiences with the drugs and, in particular, their bad trips. The study , which was reported in the “International Journal of Drug Policy,” found that many users of psychedelic substances used storytelling...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also adva...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the b...

New research conducted by a group of scientists from Finland and the UK, led by a team from University of Birmingham , has found that children who experience cognitive difficulties such as a lack of inhibition, poor memory or low attention may suffer from mental health problems as young adu...

Research on psychedelics has shown that the substances possess various benefits , some of which can be used to manage mental health conditions such as anxiety, post-traumatic stress disorder and depression . In addition, in Canada individuals who are nearing the end of their lives have bee...